
Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Koselugo
(selumetinib)
Uses, side effects, dosage information & price range
About this medicine
Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult and paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and older. Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1) aged 1 year to less than 7 years and for older patients with swallowing difficulties.
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
selumetinib
Category
Antineoplastic agents
Manufacturer
AstraZeneca AB
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.